HighTower Advisors
PACB icon

HighTower Advisors’s Pacific Biosciences PACB Stock Holding History

HighTower Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10
Closed -$1K – 3460
2022
Q1 		$1K Buy
+10
New +$115 ﹤0.01% 3371

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HighTower Advisors's PACB Position: Q2 2026 in Review

HighTower Advisors sold out of Pacific Biosciences (PACB) in Q2 2026, closing a stake of 11,287 shares — an estimated $14.9K sold.

HighTower Advisors first reported a position in PACB in Q1 2017 and held it in 24 quarters. The position peaked at $3.09M in Q1 2021. 222 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • HighTower Advisors reported no remaining Pacific Biosciences position as of Q2 2026 after selling out during the quarter.
  • HighTower Advisors sold 11,287 Pacific Biosciences shares in Q2 2026, an estimated $14.9K.
  • HighTower Advisors first reported a position in Pacific Biosciences in Q1 2017 and held it in 24 quarters.
  • HighTower Advisors's Pacific Biosciences position peaked at $3.09M in Q1 2021.
  • 222 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.